Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer

0
96

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that current Chief Business Officer Jeffrey Rona has expanded his role to include Chief Financial Officer responsibilities.

“Ovid is moving forward with a very focused corporate strategy. Combining the business development and financial functions and strategy is another step we have taken to simplify and empower the company to move nimbly and effectively,” said Jeremy M. Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid Therapeutics. “Jeff is a terrific professional and has accomplished much at Ovid. I welcome him into this expanded role and look forward to working with him more closely.”

“Ovid's plans for its future are exciting. I look forward to collaborating with the Executive team and Board to drive the Company's business and financial growth strategy,” commented Mr. Rona. “Leading the corporate and business development efforts, financial reporting and planning, and building relationships with the investment community, are critical to advancing Ovid's mission. I welcome the opportunity to take on these roles.”

Jeffrey Rona has more than 25 years of experience as an investment banker, Chief Business Officer, and Chief Financial Officer in the life sciences. Prior to joining Ovid Therapeutics, he was the Western region Managing Director for Danforth Advisors, a life science financial strategy consultancy. Previously, he held the titles of Chief Business Officer at GlobeImmune, Chief …

Full story available on Benzinga.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here